<SEC-DOCUMENT>0001144204-17-031384.txt : 20170607
<SEC-HEADER>0001144204-17-031384.hdr.sgml : 20170607
<ACCEPTANCE-DATETIME>20170607073742
ACCESSION NUMBER:		0001144204-17-031384
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20170607
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170607
DATE AS OF CHANGE:		20170607

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		17895586

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v468532_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 13 or 15(d) of </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>the Securities Exchange Act of 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Date of Report (Date of Earliest Event
Reported): June 7, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Protalix BioTherapeutics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Exact name of registrant as specified
in its charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>001-33357</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>65-0643773</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(State or other jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of incorporation)</B></P></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Commission File Number)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(IRS Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Identification No.)</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; text-align: center; width: 66%"><FONT STYLE="font-size: 10pt"><B>2 Snunit Street</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 32%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>Science Park, POB 455</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>Carmiel, Israel</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><B>20100</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Address of principal executive offices)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code +972-4-988-9488</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Former name or former address, if changed
since last report.) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01.&nbsp;&nbsp;&nbsp;&nbsp;Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 7, 2017, Protalix BioTherapeutics, Inc. issued a press
release announcing that phase II trial results, including new clinical data, for alidornase alfa (PRX-110) for the treatment of
Cystic Fibrosis (CF) will be the subject of an oral presentation at the 40th European Cystic Fibrosis Society Conference in Seville,
Spain. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01.&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>(d)</B></TD><TD><B>Exhibits</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">99.1</TD><TD>Press release dated June 7, 2017.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 51%">Date: June 7, 2017</TD>
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 30%; border-bottom: Black 1pt solid">/s/ Moshe Manor</TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">Name:&nbsp;&nbsp;Moshe Manor<BR>Title:&nbsp;&nbsp;&nbsp;&nbsp;President and Chief Executive Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v468532_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Protalix BioTherapeutics Announces Phase
II Clinical Trial Results for alidornase alfa in Cystic Fibrosis Presented at the 40<SUP>th</SUP> European Cystic Fibrosis Society
Conference</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>New clinical data reported on ppFEV1
measurement taken after washout of alidornase alfa demonstrates meaningful decrease in efficacy parameters once treatment with
alidornase alfa stopped further supporting alidornase alfa clinical efficacy</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>New clinical data demonstrate over 70%
reduction in the presence of pseudomonas, a leading cause of infections and cause of morbidity in CF patients</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">CARMIEL, Israel, June 7, 2017
&ndash; Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that phase II trial results, including new
clinical data, for alidornase alfa (PRX-110) for the treatment of Cystic Fibrosis (CF) will be the subject of an oral
presentation at the 40th European Cystic Fibrosis Society Conference in Seville, Spain. Alidornase alfa is a plant
cell-expressed, chemically-modified recombinant DNase I enzyme resistant to inhibition by actin, which the Company has
specifically designed to enhance the enzyme&rsquo;s efficacy in CF patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The oral presentation titled, &ldquo;Phase II clinical trial
results with alidornase alfa for the treatment of CF,&rdquo; will be made by Professor Eitan Kerem, Head of the Division of Pediatrics,
Children&rsquo;s Hospital, Hadassah Medical Center, and principal investigator of the clinical trial as a part of a workshop titled,
&ldquo;The airway surface, mucus and inflammation &ndash; new treatments.&rdquo; An archived copy of the presentation will be available
following the conference at www.protalix.com on the presentations tab of the investor page.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The phase II trial is a 28-day switchover study to evaluate
the safety and efficacy of alidornase alfa in CF patients previously treated with Pulmozyme<SUP>&reg;</SUP> (currently the only
commercially available DNase I therapy for CF). Participation in the trial was preceded by a two-week washout period from Pulmozyme<SUP>&reg;</SUP>
before treatment with alidornase alfa via inhalation. Sixteen patients were enrolled in the study, all of whom completed the trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In accordance with the trial design, each participating patient
was tested at three major time-points during the study for percent predicted forced expiratory volume in one second, or ppFEV1,
a key efficacy measure. The first ppFEV1 test was performed at screening, when the patient was still being treated with Pulmozyme<SUP>&reg;</SUP>.
The second ppFEV1 test was performed after the patient underwent a two-week washout period from Pulmozyme<SUP>&reg;</SUP> but before
first inhalation with alidornase alfa &ndash; the baseline &ndash; and the third ppFEV1 test was performed at the end of the 28-day
study after the patient underwent daily inhalation treatments of alidornase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Final analysis of the data demonstrated a mean absolute increase
in ppFEV1 of 3.4 points from baseline, and an increase in ppFEV1 of 3.3 points, when compared to measurements taken from patients
at enrollment before the switch from Pulmozyme<SUP>&reg;</SUP> to alidornase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the ppFEV1 measurements taken during the study,
an additional ppFEV1 measurement was taken two weeks after patients stopped treatment with alidornase alfa. For this measurement
point, a mean decrease in ppFEV1 of -2.7 points was observed from the last alidornase alfa inhalation, while patients taken off
Pulmozyme<SUP>&reg;</SUP> at the beginning of the trial for two weeks experienced a mean decrease in ppFEV1 of only 0.06 points
for the same off treatment duration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following graph describes the change in ppFEV1 for all four
measurement points. The results highlight the quick and sustained effect of alidornase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="graph1.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sputa available samples were analyzed for approximately half
of the patients participating in the study. For these samples, a mean reduction from baseline of over 70% in DNA content and over
90% for sputa visco-elasticity was demonstrated. Additionally, a clear correlation between improvement in sputa parameters and
pulmonary function was observed. Moreover, a significant increase in DNA content and sputa visco elasticity was observed during
the two weeks after stopping treatment with alidornase alfa, with a clear correlation between the decrease in pulmonary function
and sputa parameters, as demonstrated in the following graphs:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="graph2.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="graph3.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, analysis of the presence of pseudomonas aeruginosa
in patients available sputum samples was evaluated using qPCR. The analysis demonstrated a reduction of over 70%, compared to baseline,
in the presence of pseudomonas as a result of alidornase alfa treatment. This is in line and consistent with the previously announced
in vitro study of alidornase alfa which demonstrated a significant inhibition of pseudomonas aeruginosa, with colonies reduced
by over 50%, compared to baseline. Pseudomonas are a major cause of lung infections in CF patients. Chronic pulmonary infection
is a leading cause of morbidity and mortality in CF patients, despite the aggressive use of antibiotics, and pseudomonas is the
most prevalent organism in the airway colonization of CF patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alidornase alfa was well tolerated with no serious adverse events
reported, and all adverse events that occurred during the study were mild and transient in nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;The increase in FEV1 when switching from Pulmozyme<SUP>&reg;</SUP>
to alidornase alfa, and the decrease in FEV1 after washout from alidornase alfa, both in absolute terms and together with a comparison
to what was observed as part of the Pulmozyme&reg; washout period, are consistent and are very encouraging. In addition, the significant
decrease in the presence of pseudomonas aeruginosa in patients&rsquo; sputum after treatment with alidornase alfa has the potential
of extreme importance which could translate into a reduction in respiratory tract infections and life threatening complications
in CF patients,&rdquo; said Professor Eitan Kerem, a Principal Investigator in the clinical trial. &ldquo;The data set created
thus far further supports the potential of alidornase alfa becoming a gold standard treatment for all CF patients. I look forward
to participating in the future development program for alidornase alfa with the goal of having the ability to offer alidornase
alfa to patients dealing with this life shortening disease.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Protalix BioTherapeutics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Protalix is a biopharmaceutical company focused on the development
and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system,
ProCellEx<SUP>&reg;</SUP>. Protalix&rsquo;s unique expression system presents a proprietary method for developing recombinant proteins
in a cost-effective, industrial-scale manner. Protalix&rsquo;s first product manufactured by ProCellEx, taliglucerase alfa, was
approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities
of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase
alfa, excluding Brazil, where Protalix retains full rights. Protalix&rsquo;s development pipeline includes the following product
candidates: pegunigalsidase alfa (PRX-102), a modified version of the recombinant human alpha-GAL-A protein for the treatment of
Fabry disease; PRX-106, an orally delivered anti-inflammatory treatment; alidornase alfa (PRX-110), a chemically modified DNase
I for the treatment of Cystic Fibrosis; and others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent that statements in this press release are not
strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private
Securities Litigation Reform Act of 1995. The terms &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
&ldquo;plan&rdquo; and &ldquo;intend&rdquo; and other words or phrases of similar import are intended to identify forward-looking
statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future
experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations
as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause material differences
include, among others: failure or delay in the commencement or completion of our preclinical and clinical trials which may be caused
by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing
issues; lack of effectiveness during clinical trials; inability to monitor patients adequately during or after treatment; inability
or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; and lack of sufficient
funding to finance clinical trials; the risk that the results of the clinical trials of our product candidates will not support
our claims of safety or efficacy, that our product candidates will not have the desired effects or will be associated with undesirable
side effects or other unexpected characteristics; risks related to the amount and sufficiency of our cash and cash equivalents;
risks related to the successful conclusion of our negotiations with the Brazilian Ministry of Health regarding the purchase of
alfataliglicerase, and our commercialization efforts for alfataliglicerase in Brazil generally; risks relating to our ability to
make scheduled payments of the principal of, to pay interest on or to refinance our convertible notes or any other indebtedness;
risks relating to the compliance by Funda&ccedil;&atilde;o Oswaldo Cruz with its purchase obligations and related milestones under
our supply and technology transfer agreement; our dependence on performance by third party providers of services and supplies,
including without limitation, clinical trial services; delays in our preparation and filing of applications for regulatory approval;
delays in the approval or potential rejection of any applications we file with the FDA or other health regulatory authorities,
and other risks relating to the review process; the inherent risks and uncertainties in developing drug platforms and products
of the type we are developing; the impact of development of competing therapies and/or technologies by other companies and institutions;
potential product liability risks, and risks of securing adequate levels of product liability and other necessary insurance coverage;
and other factors described in our filings with the U.S. Securities and Exchange Commission. The statements in this press release
are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marcy Nanus</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Trout Group, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">646-378-2952</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">mnanus@troutgroup.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Source: Protalix BioTherapeutics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>graph1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graph1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &L G$# 2(  A$! Q$!_\0
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MYVO_ *%-6Q6/:?\ (WZI_P!>=K_Z%-6Q0 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!3U>2.'1KV26W-S&D#LT &3(-IROX]*X?PW>6-UKUG/);
MV#Z@[O"&M+EW5(UB4A\$X)P0I8C)XKJO$]MKUUI2IX=OXK.\60,SR1JP=,'*
MC((!/'.#TKD/!S+9>+)+"\U!XM5>-GFLSI]NHE'][S8EYY[$@^U$=P>QZ311
M10 5#+:6T\B23012.BLJLZ D!N"!]>]344 4?[%TL2V\HTZT\RW4)"_DKF-1
MT"G' 'M5ZBB@"I:_\?U]_OK_ .@"K=5+7_C^OO\ ?7_T 5;H **** "BBB@
MHHHH **** "BBB@ HHHH ***;)(L43R.<(@+,?0"@-S@H=!\1+\09-;:U3[-
M$DH427WFK*&'RK$A7]R20-QS@Y[TW5=#\2:OXPTG4?L:6\%N\<LA>_\ ,A3
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT445\T?MQ!%_Q]7'U7^53U!%_P ?5Q]5_E4]5+<RH_#\W^;-7PS_ ,C7H_\
MU_0?^ABOIZOF'PS_ ,C7H_\ U_0?^ABOIZO3R[X9>I\+QE_'I?X7^84445Z)
M\:%%%% !2-]T_2EI&^Z?I0!\Y4445YY^<%2+_D*W/_7*/^;U:JK%_P A6Y_Z
MY1_S>K5#+J;KT7Y%O2_^0M9?]=T_]"%?0E?/>E_\A:R_Z[I_Z$*^A*Z*&S/H
M^'_@J>J_(****Z#Z$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]"%?0E?/>E_\A>R_Z[I_Z$*^A*Z*&S/H^'_@J>J_(****Z#Z$**** "BBB@
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M0K<_]<H_YO5JJ$5S =:N(A-&9/+C&S<,Y!?(Q5^FS2JFFK]D6]+_ .0M9?\
M7=/_ $(5]"5\]Z7_ ,A:R_Z[I_Z$*^A*WH;,^BX?^"IZK\@HHHKH/H0HHHH
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M)/)I:0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4445Z)\:%%%% !2-]T_2EI&^Z?I0!\Y4445YY^<"8&<XHI:2@"WI?_(6LO\
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M_P"_R_XT?VKIW_/_ &O_ '^7_&@"W14,%Y:W+%8+F&4@9(C<-C\JFH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^J.9]@^LU/\ GU+\/\SL:*X[^P/%O_0RK_WZH_L#Q;_T,J_]^J.9]@^LU/\
MGU+\/\SL:*X[^P/%O_0RK_WZH_L#Q;_T,J_]^J.9]@^LU/\ GU+\/\SL:*X[
M^P/%O_0RK_WZH_L#Q;_T,J_]^J.9]@^LU/\ GU+\/\SL:*X[^P/%O_0RK_WZ
MH_L#Q;_T,J_]^J.9]@^LU/\ GU+\/\SL:*X[^P/%O_0RK_WZH_L#Q;_T,J_]
M^J.9]@^LU/\ GU+\/\SL:*Y:QT7Q+!?0RW6OK- K9>/R\;AZ5U-4G?H;TJDI
MJ\HN/K;]+A30Z,[('4LO4 \BJ.LVE]>6+16%Y]EE/\6W.?;/:N/T?PYXEMY;
MI1?_ &1BP+,?G$ON#752H0G!RE-)KH<]?%5*52,(TG)/JK?U]]CT"BN5_L3Q
M/_T,"_\ ?NC^Q/$__0P+_P!^Z/80_P"?B_'_ "%];J_\^9?^2_YG545RO]B>
M)_\ H8%_[]T?V)XG_P"A@7_OW1["'_/Q?C_D'UNK_P ^9?\ DO\ F=517*_V
M)XG_ .A@7_OW1_8GB?\ Z&!?^_='L(?\_%^/^0?6ZO\ SYE_Y+_F=517*_V)
MXG_Z&!?^_=']B>)_^A@7_OW1["'_ #\7X_Y!];J_\^9?^2_YG545RO\ 8GB?
M_H8%_P"_=']B>)_^A@7_ +]T>PA_S\7X_P"0?6ZO_/F7_DO^9U5%<K_8GB?_
M *&!?^_=']B>)_\ H8%_[]T>PA_S\7X_Y!];J_\ /F7_ )+_ )G545RO]B>)
M_P#H8%_[]T?V)XG_ .A@7_OW1["'_/Q?C_D'UNK_ ,^9?^2_YG545S,&C^(X
M[B)Y==5XU<%T\O[PSR*Z:LJD(PVDGZ7.BC5E43YH./K;]&PHHHK,V"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L#Q%XQT?PTF+V?=<$9
M6WCY<_AV_&M^L_5M#TW7+<P:C:1SKV+#YE^AZBHGS<ON;G1AG055/$)N/6V_
MXG.Z=\3?#EU8QS75XMI,V=T+!F*\\9('I5K_ (6+X4_Z"\?_ 'PW^%7M-\*:
M-IMA':)8PRI'D!YHU9B,YY..:M?V%I/_ $#+/_OPO^%9Q5>VK7XG;4GEG.^2
M$[7TUC^JN8__  L7PI_T%X_^^&_PH_X6+X4_Z"\?_?#?X5L?V%I/_0,L_P#O
MPO\ A1_86D_] RS_ ._"_P"%.U;NON9'/EW\D_\ P*/^1C_\+%\*?]!>/_OA
MO\*/^%B^%/\ H+Q_]\-_A6Q_86D_] RS_P"_"_X4?V%I/_0,L_\ OPO^%%JW
M=?<PY\N_DG_X%'_(Q_\ A8OA3_H+Q_\ ?#?X4?\ "Q?"G_07C_[X;_"MC^PM
M)_Z!EG_WX7_"C^PM)_Z!EG_WX7_"BU;NON8<^7?R3_\  H_Y&/\ \+%\*?\
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M\?\ WPW^%;']A:3_ - RS_[\+_A1_86D_P#0,L_^_"_X46K=U]S#GR[^2?\
MX%'_ ",?_A8OA3_H+Q_]\-_A1_PL7PI_T%X_^^&_PK8_L+2?^@99_P#?A?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!/NB">=;! SLI7&,#/0X/%4G)J]Q6C>UC5_LRW]9O^_K?XT?V9;^LW_?UO\
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M<****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !49@B-P)R@\U5*A^X'I4E% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!F3:';S7,LQEF EFCF9 5V[T((/3/8#K4?_
M  CED+V:Z4LIF8LZA4Y8C!(8KN'X$5KT57,Q61@P>$[&V#^7-<!V:)@XV J8
MR2IX7!ZG.0<U<CT2VBFCE#REDN7N1DCEV!![=.:TJ*'.3W8N5&%!X4T^VFCE
MA:0,H .Y(WWX)(SN4XZ]L5*WANQ>S2U9IC&D4L0^89Q(<MVZ\<5L44<\NX^5
M#(8S%"L;2/(5&-[XR?K@ ?I3Z**D84444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>graph2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graph2.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $/ G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH *R-7ULZ7J>CV?V?S?[1N6@W[\>7A&;.,<_=QVK7KDO%O_ ",W@_\ ["+_
M /HEZ%N@>S-Y];TF.5(GU2R61Y#$B-<("SCJH&>2/3K4L&I6%S=S6D%[;2W,
M&/-ACE5GCSTW*#D?C7DUSH>F3^"?'FHS64,EXM]=E)V7+IM.5VG^'!]*Z"31
M]/T;Q)X+DTZTBMY)5FCE>-<-(#%N.X]6Y&>:%K^'XJX2T_KL=I_;ND>=##_:
MMCYL[%8D^T)ND(."%&>2#QQ3[K5],L79+S4;2W=0I99IU0@,<+G)[D$#UKQB
MUE\)_P#""Z[;S_8_^$AEN;I;='7-R\OF-Y7E@_,1G'*\=:Z^TTBVU'XG.=6M
M8KF>#0[8D3*& <N^3@\9]Z:5_P"O*X/2_P#76QVUQK.EVEY%9W.I6<-U-_JX
M9)U5W^BDY-64NK>2XDMTGB:>( R1JX+(#T)'49KRA)O"<6C^(;;Q+]@&OO<W
M >.X4?:'Y/E>6#\Q&W9C;5F\O+SP9:Z)X@O@QFN=+%A=*023<!-T6?<D,OXT
MNG]=AVUL>C2ZSI<%I)=S:E9QVT3F.29YU"(X."I). 0>U2?VC8_98KK[;;_9
MY2!'+YJ[')Z '.#FO(M9T.329_#=EJ&M6NEV(LI7DN[ZTCGB:[9@S[O,PJDY
M;!/H13[O1["/P*MM#K<&LVEUKEN7DMHEAB&YU#*@0XQ]/6FET_K>PK_U\FSU
M(:_HS6T]R-6L#!;MLFE%RFV-O1CG /UJRU]9I9&]>Z@6T"[_ #S( FWUW=,>
M]<$?"^A#XKI;C2K06XT@2>0(@(RXD*ABO0D D9(KE+B"5?#FGVPOXM.TBWUR
M[CEFFMEGBA4,WE[E;Y=N>.>!Q2Z?UWL.W]?*Y[)%JVFSZ>;^'4+22R49-PDR
MF,#_ '@<4D6L:9///!%J-I)+;C=-&DZEHQURPSP/K7E+Z;86W@;QC-9>)K+6
M5GM5$@L+:.&*,C(!'EDJ21Z<\"MZXT33-(\4>"1I]C!;^=Y\,Q1 #*A@8X8_
MQ<C/-.W]?)_Y$_U^1TWASQEHWB@W":?>6[S02R1F$3HSLJMC> "3M/8UH2:@
M\>N0V&VW\MX'E+&X D!! XCQDKSRV>./6N/^'*Z-:7.LV$26,.K1:C=%H455
MF6$R?+P.=O3':KVH?\E4T_\ [ US_P"C(Z7;T_2XUU_KJ=%'KFD37$-O%JEB
M\TZ[XHUN$+2+ZJ,Y(^E6[BX@M('GN9HX84&7DD8*JCW)X%>-V>B:;;?"#2]4
MALH5U 74,HNMO[P-Y^/O=<8XQTKO?B5_R3C7<]/LI_F*<E;^O3_,:U=OZZG0
M0:IIUU=2VMO?VLUQ#_K88YE9T^H!R/QJ,:YI!GA@&JV)EG)$4?VA-TA!P0HS
MS@@]*\^AD\,W'B#PNGA4V9O8I&-T+51O2'RSN$O<'=C[W.:YRSE\*'X?ZM;R
M_9/^$BEN;@6Z,N;EI?-;RS&#\Q&<<KQU]Z+?U\["6O\ 7D>C:WXHUJU\3#1-
M%T&#491:BYD>:^^SA06*X'R-GI3=5\4Z]8SZ/86WAVWN-4OXI))+=M0V)#LQ
MD!]AW=?05AW>B76L_$6.%]9U/39X]$B,DEA(B,[;SD'<K<9J/QG8:1#XE\+6
MFOZQ-#9QVUPK7D][]G=V 7&Z12O)_#-%MOZ[_P"0>?E_D=*?$^J6!TA=<T6*
MR.H79M6,5YYPB8J2A)VC.X@CMCCK6GJ>N&PUK2=+BM_/FOW?/S[?*C1<L_0Y
MY*C''6L"]TS2M6^'=S9>'-02_2VS+;3K=_:2)D.\?/DDG/OWIG@K4D\6:Q=^
M)E!\E+:*SM\C[IP'E_\ 'B!_P&CKZ?U^8NG]?UL:FG>*Y-0\6/HK:5/;1BT-
MS'/.VUG ?;]S&0/J<^U=(2%!)( '))KSL>*/#[_%R-EUS364Z4;<$7:$>;YW
MW.OWO;K6[\0Q,?!-]Y0D9,QF<1@EC#O7S.G/W<TOLI_UN4_B:_K8V[+6-,U(
M2FQU&TNO).)/(G5]A]#@\466L:9J4DL=AJ-I=/$<2+!.KE#Z'!XKS_7KCPI<
M^%[[_A%CITLBQQ"\&FA2_P!E\Q?,#;/]G/!YZU)%)X9N_&'AQO![:>\L32&[
M;3]N%@\LC$FWONVX!YS3_K^O(D[I=;TEY!&FJ632%6<*+A"=JG#'&>@(()[4
M^#5M-NI)([?4+29XT$CK',K%5/(8@'@'L:\^\*:3IZ?#W5]1%I#]MD>_S<%0
M7QOD& >H&.U4KS1HK/X,:;+I<,5K)-!:M>W*P"1S$2I<L.KCN0>U+I]WXE/?
M[_P/2HM9T^^LKFXTV^M+P0JV3!,L@! Z'::SM&\46UQX1TS6M8N[*P^UP+(Q
MDE$<88]@6/\ 6N,\+:9IL>L75Y9>,-,U:4:?*C6VG64,(V\<OY9(R#T!YY-9
MRZK;VOA3PA9RVV@)+)IIDCOM=&8$QM!11D98\'&1TH_X'Z_Y"_X/Z'HVO^,=
M'\/65E=W=W 8;R=(HF$R $,0"^2>5&<DCM6A)KFDPZ>FH2ZI9)92?<N6N$$;
M?1LX->.VD5M/\,K*ZOXK*2WM/$(9Y%BQ#%#YXW%0W*QX]>U:GBM;*Z\5:;)'
MK^DZ5H+:<?L=Q-9PSVK/O.X N0BG&W'K3:_KY7#^OQL>ISZGI]M8_;KB^MHK
M/ /VB255CP>AW$XJ:&XAN+=)X)HY87&Y9$8,K#U!'!%>3C2M"L_"NG;_ !=I
M-P(;Z:YM9KV!$LI6(PT>S.W R<8/!Z5W?@F^AU'PK;7$%E!9QEI%$5O_ *HX
M=@63_98Y(^M%MQ=C7_M*P-FEX+VV^RN0JS>:NQB3@ -G!YX^M0:MJL>FV<[+
M):M=)"TR0SW*PAE& 26/1>1SC'->87VFR7]Y?^!(V(^SW<^IQ #I&5WQC\)7
M_P#':+J]_P"$D\'^*?$1S@:6ED@(^ZRKND'_ 'T<'_=I=+_U_5]"DM;?U_5M
M3O;CQOHEEXAMM$O+ZU@NIH/.):Y0*AR $.3G)SQQSBF:?XMMWU/6;;5+JRLX
M[.]6UMVDE$9DRBM_$>3ENU<]J<>AV7Q \/W>K1V$4<^F.BRW*( \H:/:,MU;
M'3OZ4RQT'2M3U3QW<7UA!<RBX,:M*@;:/)4\9Z'/<4/1-^OX,2U_#\3TG(VY
MR,=<U4@U?3+J<06^HVDTS)Y@CCG5F*YQNP#TSWK'\%RO/\/M(DD8LYL4R3U/
MRUQ6F:,D/P:O;W2K5$U6:&8FX6/=*1YAW 'J?E!XIR5FUV%%\UO,]-L]7TW4
M)I8;+4;2YEA.)4AF5V0^C 'C\:R/%'BNUT72=0DM+JRFU*UC$AM&E!< D#)4
M'('-<-X2TO36\1:9=V7C72KZZABDV65EI\,,C H01(4.0!P?F'45CW\OA@_#
M6XM[Q;1O%"RL9XRH-T)O-.6;'S!<=SQBBW]?.P7_ *^1[9!>032>0)XC<+&L
MCQ!P64'H2.H'6FMJ=@MG)>-?6PM8R0\QE78I!P<MG P:XH:OIWA_XAWD^KWL
M-C#=:7;B"2X<(LA5FW!2>IY' YKE]/GL7TG0;K5=@T(ZS>O<&X0B-6+,8S(#
MP!G/WN]&_P#7FT']?A<]#U?QUX?TBVL+B34K.6&]G6&.2.YCVX)P7SG&T<9/
M;-:,6KQW.IVT%K)9SVL]N9EFCNE+-@X&U!]Y?]H'%<%XI3PC/HVF7^F1:5)I
ML&LPFYGA1#"@)&XE@-NW&,]JT;IX9?&UF^BM T3:#.;4V^-A^<;=N.,9]*73
M^NUPZ_UWL=DNLZ6VHG3EU*S-\!DVPG7S0/\ =SFFW.MZ39LZW6J64#(XC82W
M"+M<C(4Y/!((.*\H\SPO-X%L[2Q^Q'Q9NBVQ(!]L6YWC<6'WQ_$23QBMVQT'
M3-4\5>-YM2L8+J93#&#*@;:/LZDXSTY[T/2_D-:GI (8 @@@\@BLRQUJ&:U\
MV\ELK<M/)#&$NUD5RI/ /'S8!)7J.?2L_P  .\G@'1&=BS?9$&2<G@8KS];*
MWU'1O#]I=Q"6"3Q1<AT/1ANFX/M3M[W+_6XKZ7_K8];L=1L=3A,UA>V]W$&V
MEX)5D4'TR#UK \2^)=4TK6=-TK2-&BU*ZO8Y9,2W?D! FW/.UL_>JEH-E:Z7
M\2=<M;"WBMK=[&VE:*%0J[MT@S@<9P!47B?5-/TCXC>'+K4KZVL[?[)=+YMQ
M*L:Y/E\98@4M-//_ (/^0^_]=O\ ,U-.\6R3O?6FIZ7+I^IV<!N&MFD#K(G/
MS(XX(R,=.*K>&?'2>(?#5YJ;V!M+NTC,DMFTNX[=NY"&P.&'?'K69=7UOXE\
M37.I:5*+C3[#29X9+N/F.21^0BMT; 7)QZUA7$$NB^ ='\3VL;-'_90M-11!
MDM"R_*^/56/Y$TGLWY?Y@MTOZZ'H!\3*G@F/Q$]M@R6RS+;A\DLP&U V.Y(&
M<5/X8UW_ (2+0XK][8VL^YHI[<ON,4BL59<X&>1Z5P$EUJ5YH/@O1M'LHKV=
M+>*_N(9IO*0HB@*"V#CYR#TYVUK^$;O5[+QIJVGZUI\%@VHH+Z"*&X\U"PPD
MF&VKS]TXQWJVO>:]?P_K\"4_=3_K7^OQ.VOM2L=+M_M&H7MM:0YQYEQ*L:Y]
M,D@4VXU?3;2R6]N=1M(;1L%9Y)E5#]&)Q7&^(IM'M_B#;2^)VM$TS^SV%J]]
M@0"7?\W+?+NVXZ]JSYKCPG#XJLIM0.G)X=-@?[-DG"BU$OF'S,%OER1C'MTJ
M5J4ST7^T;'[+'=?;;?[/*5$<OFKL<G@ '.#GM4 UW27MKJXCU.RDBM,_:'2X
M0B+'7<<_+^->5WEM:7/AC5$L4']A7.OVPM!'E49"R!RG^R6ST]ZZ6XT;3=/^
M(5G:66GVT-O=:1.LT,<0"2A67&X=#U-'3^NUP_K\;'1^'/%FD>)],%[87<!P
M"9(O.1GB&2/F )QTJ_::QI=_#+-9ZE9W,4.?,>&=75,=<D'BO(X?L1^$;VND
MS6<%[#-&NJ>1$KRQ1B;YO,0<D <X/4 U<T73--2XU&]LO&.F:K*-+FC:VTZR
MAA&TC.7\LGD>_/-#Z_UTN-+;^NMCT^'6=+N+M;2#4K.6Y9/,6%)U9RG]X '.
M/>LS2O&NAZQK=]I-M?6QNK67RPOGH3,=N24 .2!T/N#7"Q:)ING>!?!FH6EE
M#%>F[LV:Y5?WC%Q\V6ZD'/2MGPS'HEA\1/$=M+'80:C)<)):QE465D,0W%!U
MQG.<55K2:]?T)O>-_0[J]O[/3K<W%]=P6L(ZR3R!%'XGBF+J>GO9QWBWULUK
M(0J3"92CDG  ;.#DUR7Q#U2"Q?2K::UT8FX>39=ZS_Q[6Y4#K[G. ,CH:X.R
M47O@;5;>9K.2!_$4"8L%9("K-'GRP3D Y-3'7^O-+]1O3^O)_P"1[59ZG8:@
MTJV5];7+0MME$,JN4/H<'@_6L/Q+XMMM)T^9K&ZLKF^AGACDMC*&9 \BJ<J#
MD<'C-8EYI=MH_CVUBT6SAM'FT>X!6! H=E*[,@=2":XZ[F\*/X"TN&%;0^(4
MN;?SU10;E)/-7>9,<@=?O<=*:U:_KK83=D_ZZ7/<AR**0=!2TAA1110 4444
M %%!( )/052&KZ<=+;4Q>P?85!8W&\;  <'GZ\4 7:8\,4CH[QHS1G*%E!*G
MU'I67;:W$TVJ-<W-BEK9LO[Q)LE%*!OWF0 IYXZ\8J:QU[2-3T][^RU*UN+-
M,[YXY047'7)[4 6_LMOY4D7V>+RY23(FP8<GKD=Z<T$3M&S1(6C^X2HRO;CT
MK/T_Q+HFK6L]SI^K6=S!!_K9(I@0GU/:ETGQ%HVN^;_96IVE[Y1P_D2AMOUQ
M0!7T'PS::)9K"1'<RI/+,DSQ ,F]RQ /;K6P(8A,9A&@E*A2^T;B/3/I6<GB
M70Y=7;24U:S;4%ZVPF7?^54=+\0O-J7B.._D@AM=,N5C20_+A3&K$L2?4F@#
M;DL;26Y2YDM8'G3[LK1@LOT/44^:WAN4"3PQRJ"&"NH8 CH>>]4-+\0Z-K<4
MLNEZG:7:0G$C0RA@GUQTK/N_'7AVWT?4=1AU:RN([ 'S1'.O#= I/8D\"AZ
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ML]3LTN["YBN;>0966)@RG\17&2>.#>_$5?#VG:KI,<-N$\^.8EI9W);=&F"
M"H&3UZT=;!TN=I)86<UNMO+:0/ O2-HP5'X=*G5510J*%4#  & *RH/%&A76
MJMI4&KV4E^O!MUF4N/PKG-3\7:E:0^+WC6WSI$L*6^Y#R'1&.[GGECZ4?U_7
MW@=J+>$7!N!#&)RNTR;1N(],]<4P6=JL#P"VA$+DEHP@VMGKD=#5+4/$6DZ+
M:03ZOJ5K9+*!M,\@3)]LU8CU73Y9+6..]@=KM"]N%<'S5&,E?7&10!--:6UP
M(Q/;Q2B,[DWH&VGU&>E.6"%#(5B13*<R84#><8Y]:A34[&0792[A86A*W&''
M[H@9(;TXYJC#KD,NH7 ^U6)L8[1+H2+-F0*<_,PQ@)@<'/K0!JQQ1Q1+%'&J
M1J,!%& !Z8HBAB@C$<4:1QCHJ* !^%9MKXFT.^U 6%KJUG-=E!((8Y@6*GOB
MH-2\9^&M(O39ZCKMA:W(ZQ2SJ&'X4 :D%C9VTKRP6L$4DG+O'&%+?4CK0UA9
MO+)*UI TD@VNYC!+#T)QS5'7O$-CX?\ #UQK-U+']GBCWJ2X42$_= /J>U0:
M9XQT'5-'@U.+4[002LL9/G A9",["?7K^5 &O-:6UP8S/;Q2F,[D+H&VGU&>
ME!M+9H&@:WB,+Y+1E!M.>N16<_BK0(])757UBR73V8JMP9@$)'4 U8.N:4-*
M_M0ZC:_8",_:?-&S'UZ4 6!8V@M3:BUA%N1CR1&-F/ITIR6MO&R-'!$C(NQ"
MJ %5]!Z#VKG]1\=Z!9^%[O7X-2M;NT@!P8IEP[XX0'U-6=.\7Z#J6E0:C#JE
MH8)6\O=YP($FW<4SZ@4 :JV-HETUTMK MPW#2B,!S]3UIZP0J\CK$@:3_6$*
M,OQCGUXK('C'PT=/:_&NZ?\ 9%D\MIO/7:&],YZU?N=7TZSTW^T;F^MXK+:&
M\]Y $P>AS0!9CBCAC6.)%CC4855& !["F"SM@% MH0$<R* @^5CU8>_)YJG#
MXAT>XTP:G#J=K)8DA?M"R@IDG &?J14=OXHT&Z%X;?5[*468+7.R8'R@.I;T
MH TQ#$)FF$:"5@%+A1D@=!FH;K3[*^V_;+.WN-GW?.C#X^F16)X2\;:1XPM7
MDT^YA,\9;S+=90[(H8@,<=CC(K<2_M)+BXMTN(VFM@#,@;F,$9&?3(H DC@B
MBA$,<2)$!@(J@+CZ4?9X?L_V?R8_)V[?+VC;CTQTQ59=8TU[&"]6]@-K<,J0
MRAQM=F.% /?)KG-6\>V7A_1Y;_4Y[$G[:;6)(+C.0'"G)(X90<D=L4 =7';0
M1.'C@C1@H0%4 (4=!]/:G-#$\J2M$AD0$*Y497/7![5R=QXWLEUW3##J%DVB
M75G/.]V7&W*,H&&SC')%=+I^HV6JV:7FGW4-U;2?=EA<,I_$4P)+FTMKR+RK
MJWBGCSG9*@8?D:2:RM+B 03VL,L(Z1O&&4?@>*H:AXGT+2;R.SU#5[*UN9/N
M12S*K'\#5>[UFYA\::9I,8B-K=6DT[DCYMR% ,'/3YC2!Z&RUM T2Q-!&8U(
M*H4& 1TP/:G&&(S+,8T,J@J'*C< >V:R+3Q#:IX=35M4O=/@AYW313[H1@D<
M,0,U3T?Q0FK>)M2M;>XMIM-@M()XIXFSG?NW9;.,?**.H'01VEM"\KQ6\2-*
M<R%4 +_7UIL&GV5LKK!:01+)]\1QA0WUP.:I:=XFT/5[N6UT[5K.ZN(OOQPS
M!F7\!0OB71'O%M%U6T-RV_;$)1N.S._CVP<_2@#0-M;F*.(P1&.,@HFP87'3
M [8H-K;M<BY,$1G4;1*4&X#TSUK-M_%.@W=]#96^L64MU,GF1PK,I9E]0*6[
M\4:#8ZDFG76KV4-ZYPL#S*')^E &C<6MO=Q>5<P131YSLD0,/R--^QVNTK]F
MAVE@Y&P8+#H?J,"JFI^(='T:2&/4]3M+1YSB)9I0I<^V:-5\0:/H:1OJFI6M
MFLIPAGE"[OIF@"^88C,LQC0RJ"H<J-P![9J+[!9^9))]D@WR$%V\L98CIDXY
MQ4L,T5Q"DT,B21.,JZ'((]0:S(?%&@W&K'2H=8LI+\?\NZS*7_*@#6HKB-0\
M<_V._BR6_>V2#2FC2V#?*9&:(,%)[DD]JD\/^-+3_A&TU77_ !#HICE?Y);=
MO+1>!E#N)R1GF@&=G14-I>6U_:QW5I/'/!(,I)&P96'L14U !1110 5Y5/ R
M>))/ (#?9;O4!J0(' M?]8Z_]_1CZ-7JM)L7?OVC=C&<<T+1W_K^KATL>874
M.F33>.XM5NFL[0W]MF=4W"-A%&5)&#QD#.>*J3:DVK^$KTK%;7EA:ZA;M/>6
M%N42\@!!8[>^.^,CBO63&AW91?FZ\=:%157:J@+Z <4?\#\ 9YMK^J^'=;T-
MY]!6"\M8+FV;4C:09WP!B2IP/F Y)7FI4O=*\0^+].N?",D$GV:UN%NKFV3$
M8#* B,0,$[N<=L&O1$C1 0B*H/8#%"1I&,(BJ/11BC^OPL!X;X=L;"=-)T_4
MO&5S%JD-S&\FE_8(EE697!^\$WX)_BST/)KI[G4&TM/'EVEG%=[=1@!29-T:
M@QQC>P'4+][\*]*\J/?OV+O_ +V.:78OS?*/FZ\=:=_Z^[_(+?U]_P#F>-Z!
M=P:AXJU62\U6ROK"71G62XTNR:%-N_D#D[R,GD=*OZ/=V^H:5K6C:?)8ZQ:Q
M:6PAO[:V","!@1/@8+=^/RKU18HT&%15[<#%*D:1@A$50>P&*3U5@6CN>6MJ
M.F7_ ( \,KITL3M;W]C#<"-<%)!@,K>XJU#JGAW1O$/B.W\4>0MW=W>Z$7,)
M<SP[ %"<'<!R,"O1Q%&!@1J!G. ._K2M'&[!F16(Z$C.*;=W?^N@DK*QY=J%
MM]KT3XDQQP^:WFY1 N3Q AX'K5_5=0TZX\)Z9XJT.2&>+1IEEE:!>L6 LR_7
M:2?J*]#"J,X4#/7CK6?K.CQZQHESI9E>VAN4\N1H0 =I^\/Q&1^-+T\OP*T;
MU\S(\"PF72)]9E4B?5[AKMB>H0\1C\$"_G7._P!J^']%\2>)8O%7DI=7=P&M
MC<0[O/@\M0J)P<X.X8'<^]>C0PQV\$<,2A8XU"JHZ #@4YHXW(+HK$="1G%#
MM?3T$KVU/++#3G@L?A]#?6X#_;)MJ2I\RQE)2BG/HI7BNP\>Z7<ZKX*O[6QC
MWW 59(XP<;]C!MOXXQ72%5)!(!(Z<=*6AN_]>G^0+?\ KS_S.4TSX@^']2-M
M:VMS)+?R;5:S6)O-B)Z[U_A [DUS_@[PPE_>ZIJ9UG6H#'K%P?LUO>LD#;7[
MH.#GOZUZ2(XU<NJ*&/4@<FE"JN=H R<\"G?6X=+''_%/9_PKS4O,4LFZ+<H&
M<CS5XK'@O]$U7QCH1\,1QLUA%-]L$$.SRXRF!&_ P=V.#Z5VWB#18?$.C3:9
M/*\4<K(Q>/&1M8-W^E:*1HF=JJ">I QFDM/Z\K _Z^\\,N-<EU34=$=+G2;9
MH]6@+Z9:V++/:YDQ\\N<#.>>.<UV>BW&FV/C7Q9ILWDPZA<3":VB*89X_(7+
M+QTR#FN_\J/)/EKDG)..M+Y:%]^Q=V,;L<T=+>OXV_R#K<\6EBE'A#P/=3ZI
M)IFEQ02":Z2W2812$?(6#J0!@,-V.,^]2W6GZ8_@C4Y;37)-;AO=2M/.E:!8
MHR=Z@A0BA3D=2*]D\M"FS8NS^[CB@11A-@10H[8XIWU_KR_R$M/Z]?\ ,XJ\
ML+2S^)6B16MK#"DVF74<B1QA0ZJ8]H('7&3^=<[H<WAVY^&U[H]_>+9S6LC+
M>,D67MV\TE"XQTR!UXQ7K&U2P8@;AT.*;Y4?S?(OS?>XZ_6ET_KO<?7^NUCD
M? .K_P!J1ZBJ&RN889$5-1LH?*CN@5ST]5Z'&1S6#XFU#3-(\6WEQ:7=I<ZE
M<&%+C1[JV+O/C !B;&1P<]QQVKTY45%VHH4>@&*0QH7#E%+CHV.:=]4PZ-'E
M<>K>&-+\:^,7U](8Y9I841IH=V\>0GR*<=?:F6LA\-V7@/4]:9[:SMHKB*66
M4'$ D7,8?TX '->B6&@VUCJNJ7X9I'U&5)75P"$*H$&/P%:;(KKM=0R^A&:$
M[6^7Z_Y@];_UV_R/*9IH?$&F_$2:RB>>.6)##NB(+XBZJ",_0U-J_BW3!H>A
M-I4^D16DH='U.[MS)#;2*BY7:,?,V<=1TKU$(JYPH&>N!3?)BV;/*3;UV[1B
MEY>@?\$X+X422R:9KAEFCF_XFDA#Q0&%""B'*H?N@YS1+9M)XU\7BRB07ATN
M'R6"C(D*R8(]\UWX55SM &>N!1M4,6 &3U.*'K]UOPL"T^_];GD+7_A_4?"6
MDZ%H\<8\1Q2V^V!(")K>174R._&5X#9)ZY]ZGUS/V3XCYZ^?:_\ HJ.O5A'&
MKEPBACU8#DT&-#NRBG=UXZT[]?ZZ?Y!;2W]=?\SSRXU+1]#\:W=UXF:&&">R
M@2QGN8\I@ [T4] <X..]9:1#3/#4?B2*)K>PL=9DO+9"A4K:.=K84] 02P'T
MKU=XTD #HK = PS2E59=I4%>F".*5_Z^=P_K\+'C#QW%G$MK^\5_&D*L6 ^[
M(9,OGW\IQ_WS71:I$D'B/Q9#&H5$\-HJ@=@!*!7HFQ#MRJ_+]WCI2E%))*C)
M&#QU%#U5EY_E9?<"W3]/SN>7G3;*P\-^ 9K2TAAE^VVWSH@#'<AW<^_>N=BN
MK+4-3NM#O-6\/VD$FKO.YGD;[<I67<%Z;>=HP<]#C%>XF-"H4J,#H,=*XAOA
MK;GS;9=;U!=)E9F?3PL6T[CDC?MWXS[T^;WK_P!=/\A6TM_77_,WO%MM]K\&
MZK!'$)2UI)L4#.3M.,5PNH7.C:[X+\*Q69@N+<:I:0W"*N!O"G<K#U]:]3CC
M2*)(D&$10JCT I!%&HP(U SG '?UH6C^[\!]/ZZGF7CRU6R\4Z7<3ZN=#TA;
M61%N8[2.6-)MP.&WJ0N5[^V*@2XL_#_@F2ZT_4(M9@N]1#/?WUJ!!;DCF38J
M@;1CJ.,FO56177:ZAAZ$9H\M-FS8NS^[CBETL'4\4TSSM5L_'RBYM-2,NF1O
M')9V9ACD;9(,JI)R>,9'7%;E_<:)X@T#PA'9_9[JS_M2"*957Y2XC.5(]>F:
M]/6-%^ZBCC' [4@BC4 "-0 <@ =#3O\ I^%_\Q-7_']#A+71-+;XIZR6T^V.
MW3(" 8Q@$EP3CID@ ?A7'>5.?!WA2XEU.73M+MKB[2:Y2W280'>XC)5E( P"
M,XXS7MVU=Q; W'@G%)Y:;-FQ=O\ =QQ2Z?UW?^8_Z_!+]#QN[L=,?P-KEQ9Z
M_)KD=W=6HFE,"11\2*/EV*%/'4BNNN]/L['XB^'(K6U@@22PNHW6.,*&4>7@
M'U KM1%&$V!%"_W<<4[:I8,0,CH<=*=_Z^5@>UOZW3_0X7X97>G#2;C2XFB7
M4K2XF^TPA</&#*VW=QW[54\<RRZ-X@6>V)5M>M#I@*CI-N^1OR=_RKT0(BL6
M55#-U(')I616QN4'!R,CI2[7#N>7:'9B+Q1:>#PK+;Z)=R7JKV,14>5_X\[?
M]\U4O(D?X=ZY*\0=8-?:5SMSM07"EC],9S7KFU0Q;:-QX)QS2;$VE=HP>HQU
MIW?]>J?Z"LOZ]&OU//IO[&U_Q[X8N;9+:[L#8W,D!" ID,HR!T]:T_!D:6^N
M^++>%%C@34@5C08528D)P/<\UURQHN-J*,# P.E*%4$D  GDX'6B_P"OYC>O
MX'C_ (^UN26_UW2_-TG3G6$JD=Q8M/<7P*9W(01@#IGG&*W-)=I/$7@MW8LS
M:#(22<DG$5>AM'&S;F12PXR1S0$4$$*,@8''04EHK?ULU^H2U_KT_P CQ[39
MK:R\,^#-0U0#^Q[>XN#<,Z;DC<E@C-[ YY]Z2Z:VU6Z\:R^&[<F":PM6/DQ%
M1.NYMY0<9RH(R.M>Q>6FS9L79_=QQ0J*OW5 XQP*=_Z^[_(;?]??_F>;?VEX
M>UW6_#47A80/=6=SOF-O#M\B$(0RN<#&>!@]ZM^#K"T70/$%X+:+[2]_>[I=
MOS'#,!S]*[Y8T0DHBJ3UP,9I0JJ" H /4 4GJFN_ZB6C3['DD>FV5I\*?#%U
M;VD,=Q]JLY/-5 'W-( 3GKSDUF>/]<DN5\16*S:3I\D191:R6+2W5T !B4,"
M,#T/.,5[;L3:%VKM'08X%(8HV;<T:EL8R1SBFW=W_KI_D"T_KU_S/+O%.H:;
MI=[%J*ZC:_VLUA'&VG7UN9%O% W!4.,AN2.,]>153Q&3'XRFN]8\02>'K6XL
M8/LK-:12IWWQ[G0A2">@QG/M7KICC9@S(I*]"1TH>-)!AT5AZ,,T CG_  99
MVVG>$K:&RO9K^ !W2:6/RR^23PN  /3BO*[W7)=4O])*7&DVKQZO"7TRVL6%
MQ;_O<9>7.!G//'.:]V  & ,"F>5'N)\M,GDG;UHO[UPZ6/,-71'B^)H=58!(
MR,C.#]G6I/$6KKI%MH5I'_96FQRV>\:C?VOFHK87]VJC'S'KU[5Z840[LJOS
M?>XZT-&C@!D5@.@(SBETMZ?J._\ 7W?Y'#_"AI#X7NQ)(KD:C<8*1&)<;\_*
MA^Z.<X[5W5(%"_= &>>!2TV[DH****0PHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@?\ 007_ +]O_A69/XQEC\8V5G$+>31;BW0FX .]9'9@G.<;<H5(QG)%;O\
MPCFC?] RU_[]BJ>H^#]*U)+I)!+$EQ;);$0L%V*K%E*\<$$]:*/MU+][:WE?
M]0J^P:_=7OYV_0Q]/\=LVH:J;^.);&.2)=/\H?O)PY<<DG')0D'@8K4E\:Z7
M#IR7Y2X-ON996"K^Y*G!W?-S@]EW&EN?!6D7*%2LB82%(]NTB/R@0A ((_B.
M<@@^E5[[P#INH6ZPW%S=$"(PN52%=ZDYZ"/"D$]5"GUS71H<Y=3Q78OJAL1!
M=C%S]D,YB_=^;MW!<YSR.^,5+?\ B".TO9K.*TN+F>* S,(R@ &"0/F8$YQV
M!]\4J^'+)9"X>;)O?MWWA_K,8QTZ8HOO#\&I:I!>W-S<,(/]7  @0'!!.0N\
M]3QNQ[4NA1G:=XSBN[73FGTV\AN+VW-QY8"L$08W,6W8 Y^OM3X?'.D3Q2R*
M)P$C$L8(7,J%@H9?FX&2/O8Z\U:L?"]G9&#,]Q.(+9[5!,5P(F(.WY5&<8 !
MZ^N:@LO"%MIMK-;V=[<0QN@C4+#;DQJ#T!,1+#M\^[^M BW!K\5Q?06:VER)
MI(Q(P)C_ '0.<;OGYZ?P[J74/$-IIE_!:W,<X\YUC$H4; S' ')R<^P..^*J
M6_A"SMWL<7=V\5DWF11-Y>-^22Q8(&ZD_*"%[8Q2W_@_3]1U@:E-+<"0/')L
M4H5W(<J<E2P]P" ?2@"$>.=+%J]U)!>Q6XBEECD>( 2B+.\+SG(QWQGM4-_X
ML+R6D%HEQ:W!O+99([B( O#(Q 8<G@X([$8[503P)/\ \(K<6D]T\U^;>YBM
MD>0>3"TN[D84'D$=<XYQ6S!X/M 8IKJZN[FZ1X7\V1U) B)*H,*/E!)]SGDT
M 4[;QY816<37S[Y=AEF:!-JQ)O90S!FS_">F3P3BI9?%/VK7-)M;".X^RS7D
ML$EP8QY<NR-R54]>&4<X&<'&:<O@72XI898)9XI8TV%]D,A==S, =Z,!@L>1
M@\]:LV_A.SMM1@NX[N\\NWN)+F&V+KY2.X8,?N[L'<3@G@GC%-6OJ#\C>HHH
MI %%%% !1110 4444 %%%% !1110!G:GKNFZ,T:ZA="$R@E,HQSCKT!]:H?\
M)QX<_P"@DO\ WZ?_ .)K<EMX9\>;#')CIO4'%1_8+/\ Y](/^_8_PK2+IVU3
M(:G?1HRH/&.@7,Z0Q:BC22,%4&-QDGW(K TSQQ?7&BZE)=P6PU&*4K9QQA@L
MJLY2/())SE2#@]NU=JME:HP9+:%6'((C (K%A\&:5#=Z?<CSVDL/,\K<XPV\
MDG<,<X+''IFIERM^Z./-U,W3/'UJVCZ?-J@ NY;:.:Z^S@>7!N. 3N;.">PR
M?6M.^\8:;IMS/#=1W*>5#),&V#$@0;F"C.<X]0 >QJ"+P+I=LUL]M+/$\$:1
M%BD4AD53P&WHV.IY7!ID_@#2;FYN)I)KO,RS*5!3Y1*"'P=NX]>,DX[<4GN4
M:VEZ];ZK)<1)!<P2P*CM'<1[6*,"58<G@X/OQR!6:/'.EBT>[D@O8H!!)/&[
MQ >:J?>VC.<CWQGMFM>#2H+:\N+N)G\V:".!@QXVINV]NOS&N37P'/\ \(G-
M9RW<DVH&TFMX%>0>5"9,YVD*#SQUSCM1I<%YEO6/&8@M!]FVV%P+F".0ZC%\
MJ12$@28#CC@]QTY%,3Q)J,VO6^GPZA9S0M;I-]HM]+FF60L[#JDA$8P.K$]Z
MTH/"-HICFN;F[N+I9(9#-(Z[OW62B\*!M&3VR<\FK=SH7G:Q_:<&I7MI,T2Q
M.L(B*NH)(!WHQ[GH11I<6IE0>)KR98;$1V_]K?V@UI-'M.U43+%P,YP4VD<]
M6%7?#^JZG?ZAJUMJ4%M"UI,JQK 2WRLH;YB>IY[ 5/%X<L(?$TVOKYOVV6$0
ML"WR <<@8^\< $^@%&F:#_9FI7E]_:5[<O=D&1)Q%MR  "-J*> ,=:%_7]?U
MN-FO52]U*TT_9]JF$>_.WY2<X^@]ZMTQXHY,>9&K8Z;AFIE>WN[@9O\ PDFD
M?\_@_P"^&_PIT?B#2I9%C2[4LQP!M8<_E5[[+;_\\(O^^!2BW@4@K#&".A"B
ML[5>Z^Y_YBU.*TWQQ=R0:U]O@@6:VED%DL0(\Y1(T2@Y)^;<N#CU%2:7X]B7
M1;276547[(\ERMJ,)$JNR;OF;./EZ#)]JU!X,TH7-E<'SV>SN9;F/+C#-(Q<
MAACD!CD#M@5"? NEJT3PRSQ2QAE,FR*0NI<O@B1&'5CR #[UMH-^1:G\6:=;
M7K6TR3I^[>1)"HVR!%W, ,YZ<\@ ]C4VC^(K769GBA@NH'$*3JMQ'MWQOG:P
MY/H>#@^U9[>!=+>_DNVFNMSF4[<IA?,4JV#MW8Y. 20.W'%:UEHUM872W$32
M%UM8[4;B"-B$D=NO)I+S YRV\2ZPEK#J5V;*2RFOVL_*BA=)(_WA16W%R&Y
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MJ6D P ,Y]S2T@"BBB@ HHHH **** "BBO,-<GQXWGF1HR\-Y;HJ%L78.U?\
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M *^%_D:N=JIW_P!ZT_Z^%_D:Z2RY33&A;<44MZXYIU% #2B'&47CIQTIU%%
M!1110 4444 %0"SMA>O>"%/M+QB-I,<E0<X^G-3USFLWVKV>LV%O:7=FRW<X
M MWM6+)$HS(Q<2=@./EZD"@#0M_#VDVLLDD%C$C2*R,1GA6Z@>@/MBI?[&T[
M[5;W/V.+SK=0D3 ?< Z ?3MZ5R=KXPOK^VEGMGC\V6-WMK,V$VXJ& W!R0)2
M%Y*KSVS5[0_%4NHWMO9W<EK;SA6$J."CROD[0B$Y7@ D'.,XZ@TTF)^9UE4]
M/_Y>O^OAZLS316\9DF=40?Q,<"JFER)-'<21L&1KAR&!X-(9;F_U35B:I"DD
M$;,#N$L:Y!(X+J#T]JVYO]4U9&H?\>R?]=X?_1BUS8A7BQTVU45BT   !T H
MHHI&04444 5K[_CW3_KM%_Z,6KS?>/UJC??\>Z?]=HO_ $8M7F^\?K6M#XI?
M+]31_ OG^@E%%%=)F%4]6B632[DMG*1LZD$C!"G!XJY574O^05>?]<'_ /03
M3CNA/8FMXUBMT1!A0O'.:DIL?^J3Z"G4, HHHI#(;N-);*=)$5U,;95AD=,U
M#8Q1PV4*Q1H@* D*N.<58N/^/6?_ *Y/_P"@FHK7_CTA_P"N:_RK*L_=0NI+
M1117,,**** "KZ_='TJA5]?NCZ5K3ZE1*DW_ "%[7_KC+_-*N5GWEQ#;:G:/
M-(L:F*498XYRE7D=9$5T8,K#(([BM2B*6SMI[B*XEA1Y8E949ADJ&QN'XX%0
M:?HVG:5O-C:1P%\!BO<#H/H,GCI6)<Z]J-MXJBTT&)X9EE*J]K)'@JN5"R,=
MLA/=5''/I4_A;6+C4HWCO[I#?+%')):_8);5X<@YR)"2PR" 1QQ0O(&=%111
M0 4444 %%%% !15<7]FTQA%W 902"@D&[\J1=0LGC:1+RW9$QN82@A<],G-
M%FBFAT+!0R[B,@9Y(]:=0!3TK_D%6O\ US%69?\ 5-]*K:5_R"K7_KF*LR_Z
MIOI2>P%*BBBN8S"BBB@ HHHH DHHHKN **** *>J_P#('O?^N#_^@FK@Z53U
M7_D#WO\ UP?_ -!-7!TJOLBZA1114C"E'?Z&DI?7Z&D]@,_2O^019?\ 7!/_
M $$5;JII7_((LO\ K@G_ *"*MURS^)BCL@HHHJ!A4%I_JF_ZZR?^AFIZ@M/]
M4W_763_T,TGN@-?M5._^]:?]?"_R-7.U4=3\S;;>5MW^>N-W3H:ZS0O4PRQB
M01F11(>0N>?RHA\WRQYP0/WV$X_6N,UR;2;SQE860>WM[NVGCN)[AL*['&%B
M4]3GC..,?6CK8.ESLY)8XL>9(J9.!N.,FGUP&OW5C?ZJ]Q=*9M/DT^6*V\R%
ML?: Y!"@C.[CCU[5V&B)<1Z%8)=;OM"VZ"3=UW;1G-'2X=2_1110 4444 %4
MO[+MSK/]J,7:X$/D*"?E1<Y.!ZGC/T%7:PM4UG4=-U&TA&G6LT%U<+!$PNV$
MIR,L=GEXPH#'[W0?A1U 6T\+6=E.)(KBZQ$LB6T9==ML'Y;9QG_OHG'0<4+X
M4TV.\M;B,S+]GVXC##;(RDE6;C)(+,>HSGG-9]SXXAAU/5+2.Q=X[&%7^T-(
M%21MVUATX"GJWUXXJ_HOB1=;, @M2"49YVWY2+!( !Q\V[!(Z?+SQD"FK]!.
MVS-VJ>G_ /+U_P!?#U<JGI__ "]?]?#TAEF;_5-61J'_ ![)_P!=X?\ T8M:
MTW^I:L36+B*UL!+,VU%FB)/H ZG^E<V(=HMOL533=1)%^BLV/Q!I,IPM_#GT
M+8JW'>VLO^KN87_W7!J(U(2V:9,J52/Q1:^3)Z* <\T51F5K[_CW3_KM%_Z,
M6KS?>/UJC??\>Z?]=HO_ $8M7F^\?K6M#XI?+]31_ OG^@E%%%=)F%5=2_Y!
M5Y_UP?\ ]!-6JJZE_P @J\_ZX/\ ^@FG'=">Q8C_ -4GT%.IL?\ JD^@IU(8
M4444 1W'_'K/_P!<G_\ 0345K_QZ0_\ 7-?Y5+<?\>L__7)__0345K_QZ0_]
M<U_E65;X4+J2T445S#"BBFR.T<998VD(_@4C)_,@4P'5?7[H^E9-G=?;+<3"
M&2($D 28R??@FM9?NCZ5K!6;3*CJ5)O^0O:_]<9?YI5RJ<W_ "%[7_KC+_-*
MN5H48\OAZ&XU!;NXO+V;RF9X(GD 6%F!!92 &S@G&2<=L5+I^BQ6%Y+>O=7-
MY=RQK$9[@KN"*20H"JH R3VR>Y-9UUXMCL-:>QN8(O*2.25GAN!))&J+N+21
M@?*".AR?H*GTCQ!-?WRV=Y8?9)9;87<&)O,WQDXYX&UAD9'(YZFA>0/S-VBB
MB@ HHHH **** .1NM/MM2\57$IM%AMM,@8M*D/S232*<D8&6VK^K>U8EO9)<
M:9<V"20RZ?8Q12Q7L%AM\QQN7RV3/SG&#]2*])HH#K<X/PM+?6&O_P!FW=H6
MD$*Q^8Q)>*-44J,XV[<DCCDL#[5V\_VC ^SF+/?S,_TJ6BFW<"EI.?[(M<XS
MY8SBK4O^J;Z56TK_ )!5K_US%69?]4WTJ7L!2HHHKF,PHHHH ***CEGC@ ,C
M;03@47L!8[44BL&4,IR",BEKN0!1110!3U;_ ) ][_UP?_T$U<'2N:UWQ##Y
M%UI]C&UW<F)A(4^Y$,')8_TJ8W/BE5&-/T]OI.:U]F^770SYU?0WZ*Y];SQ1
MGYM+LL>UQ0VH>)@<#1;<^XN12]F^Z^\?.NS^XZ"E'?Z&N?&H^(PN6T*(GVNE
MI!JOB#OH"XQ_S\K2=-VW7WH.=?TC1TK_ )!%E_UP3_T$5;KF]$\1VGV6UL[Q
M'LYQ$H43<+(,#!4UT@((R#Q7'5A*,GS(<))K0****R*"H+3_ %+?]=9/_0S3
MYY(XK>1Y<; I+9]*I:*D/V(3QP1Q&5F/RC'&3@?A2NN:W4#H>U4[_P"]:?\
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M'XF.&Q0O+>&YU.T2>&.5!%*=LBAAG*>M7D18T5$4*BC"JHP /2JLW_(7M?\
MKC+_ #2KE66<SJGA676[X/J%W";9/-"+#!LD(="A5GW'( /3 Z"K&CZ#<V5\
MEY?WR74T-J+2'RX?+"H#DD_,<L<#/0<=*L2>(;*'4UL)TN(I'W^4\D1"2E1E
M@I[D#FIM)U:/6+<7$5K=0Q,JNC3Q[=X89!'-"VT!^9H457GOK>VN+>"5\2W#
M%8UQU(&3^E5--\0Z7J]W<6UC="66 _.-I /.,J2,,,\9&>: -.BBB@ HHHH
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M!_P(UAZ+J]F][.MS+Y5],V=D@VY'8*3UK=M/]2W_ %UD_P#0S7,H23YI+?\
M+H4FGL:_:J=_]ZT_Z^%_D:N=JHZFK.MLJ2&-C.N& !(X/K7::EZHVN(4G2%Y
MHUED!*(6 9@.N!WI84>.,*\K2M_>8 $_E7(ZNEG#\0M'NUM)VN-DB33I;2.
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MDMO)'"4#NI4%^G(J&T26.V2.8H64  ITP![U<C^_^?\ *H:QK/9!;J%%%%8
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MN-WM+;[,@C*JPR48\LX7^\<$]JN:%XHGN[^VLM0N%BD0-&^8^9Y-Q"@D#:I
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M% %/2O\ D%6O_7,59E_U3?2JVE?\@JU_ZYBK,O\ JF^E)[ 4J***YC,****
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MX4?86_Y_KO\ [Z7_  JHQY1I6";_ )"]K_UQE_FE7*HG3 TJRF\NMZ@@'>.
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M^!4O_P 51S!RB[3Z&C:?0TG]F6_]ZY_\"I?_ (JD;3K5%+-)<*HY)-U( /\
MQZCF#E';3Z&E"G/0]#6*MY8OXCBTJ-WF$D+2"2'4)'9"I&0ZY^4'/!SS@UL?
MV9;_ -ZY_P# J7_XJDV'*-VM_=-&UO[IIW]F6_\ >N?_  *E_P#BJ/[,M_[U
MS_X%2_\ Q59>S#E&[6_NFDVM_=-/_LRW_O7/_@5+_P#%52U-M,TF&.6ZDO )
M7$<:I/*Q9B"0  WM1[/S#E+>UO[IHVM_=-9NAW6FZ_9O=6BWZ1+(4!EGD7?C
MJ1\W([9K4_LRW_O7/_@5+_\ %4>S#E+E4[_[UI_U\+_(T?V9;_WKG_P*E_\
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M::S&BW)E1ER!)#(4?:2-RY'8X&:NV]O#:6T=O;QK'#$H1$48"@= * ):***
/"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>graph3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graph3.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !] G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MJO*GF3HA=U&TGY6QZ4 6**K_ &1?^>DW_?PT?9%_YZS?]_#0!8HJO]D7_GI-
M_P!_#1]D7_GI-_W\- %BBJ_V1?\ GI-_W\-'V1?^>LW_ '\- %BBJ_V1?^>D
MW_?PT?9%_P">DW_?PT 6**K_ &1?^>DW_?PT?9%_YZ3?]_#0!8HJO]D7_GK-
M_P!_#1]D7_GI-_W\- %BBJ_V1?\ GI-_W\-'V1?^>DW_ '\- %BBJ_V1?^>L
MW_?PT?9%_P">DW_?PT 6**K_ &1?^>DW_?PT?9%_YZ3?]_#0!8HJO]D7_GI-
M_P!_#1]D7_GK-_W\- %BBJWV>(?\MY/^_IH^SQ?\]Y/^_IHN!9HJM]GB_P">
M\G_?TT?9XO\ GO)_W]-*X%FBJWV>+_GO)_W]-'V>+_GO)_W]-%T!9HJM]GB_
MY[R?]_31]GB_Y[R?]_31<"S15;[/%_SWD_[^FC[/%_SWD_[^FBZ LT56^SQ_
M\]I?^_AH^SQ_\]I?^_AI@6:*K?9X_P#GM+_W\-'V>/\ Y[2_]_#0!9HJM]GC
M_P">TO\ W\-'V>/_ )[2_P#?PT 6:*K?9X_^>TO_ '\-'V>/_GM+_P!_#0!9
MHJM]GC_Y[2_]_#1]GC_Y[2_]_#0!9HJM]GC_ .>TO_?PT?9X_P#GM+_W\- %
MFBJWV>/_ )[2_P#?PT?9H_\ GM+_ -_#0!9HJM]GC_Y[2_\ ?PT?9X_^>TO_
M '\- %FBJWV>/_GM+_W\-'V>/_GM+_W\- %FBJWV>/\ Y[2_]_#1]GC_ .>T
MO_?PT 6:*K?9XQ_RVE_[^&C[/%_SWD_[^FBX%FBJWV>+_GO)_P!_31]GB_Y[
MR?\ ?TTK@6:*K?9XO^>\G_?TT?9XO^>\G_?TT70%FBJWV>+_ )[R?]_31]GB
M_P">\G_?TT7 LT56^SQ?\]Y/^_IH^SQ?\]Y/^_IHN@+-%5OL\7_/>3_OZ:7[
M(O\ SUF_[^&F!8HJO]D7_GI-_P!_#1]D7_GI-_W\- %BBJ_V1?\ GI-_W\-'
MV1?^>DW_ '\- %BBJ_V1?^>LW_?PT?9%_P">DW_?PT 6**K_ &1?^>DW_?PT
MD *7$T>YF4!2-QSZT 6:*** "FO]W\1_.G4U_N_B/YT .HHHH *B/_'VG^X?
MYBI:B/\ Q]I_N'^8H EHHHH *BN;F&SM9;FYE6*")"\CL<!5 R2:EK'\4Z3/
MKGAN\TZVECCFE"[&D!*DJP;!QV.,'ZTUOJ)[&-;?$;1)GU"ZEO(H]*MVBBBN
M"K[I9&4LP"XSP,=JTY_&GARVD5)=5A5FMQ=#"L1Y1&0^0,8Q7-/X*\1+<G4H
MM0TYM3DN)WD+Q-Y:I)&J J.NY0N!GJ#4\?@"6WTN^T^*XB:*X>SB#.#G[/"%
MW*?<D-[?-6C4.Y"<C8?Q]X6CLDO'UB$0/(T2MM;EE&6XQG R.>G(JPWC#0%F
MN8FU*,/:PB:;*MA%.,<XQGYAQUYZ5R^H>!-8GFOWM;VRC_M!KA)RZ,2L3NI4
M)Z':H4U'JGP_U?4GU5S=6427,T,B6T32I'+Y;9W/@Y5BH"Y7TS1RP[A>78[B
MQUO3=2TG^U+2[CDL0&)F.5"A?O9S@C&#UK"N/'^D2VD%QI-U'=HUY';S$JZ^
M4K!F+8(!.%4FIIO#$K^ 9= A-M;7$D!4M$&\LN3DYR2Q!/4DY.37.ZCH&KZ7
M;RZQ>-'=W?GRS>38PL=SM (855?123R>U*,8L;<C2T?XE:1=:='>ZG>6UFMU
M*XM(@LA<HK;06^7J>/;G%=N#D9KSP^!=5/V2*&[M4LFM;&&Z21"9/W#;BJGI
MACR:]#I3Y?LCC?J%%%%04%%%% !1110 4444 4)209"HR1D@>M<E:^.[.XN-
M(A>V>)M0M);ALM_J2F?D/N=K?E77,<2$^]><W?P[OY8-36"^@266[$EDQ!_=
M0DN74^Y\QOTK*"@V^8RE?H='IOC/2+Y;:.:X6UO9K?[0;>0'Y%V[OO8VD[><
M9JG=_$#1K>739TNXVTRZ,RR7)1P49 " %QDYSZ5GW'@;46\5KJ275K+9Q*5A
MBG+G"F'RPA3.W;GG.,D&I-+\%ZG:I9_:KNW?R!=A8E9W6)98PJJI;)(&#U]:
MOEI;W)O(Z&;Q5H4%_:V,FIPK<W2HT*<G<'^Z<@8&>V2,U'?^+M'L--DO6N?,
M54F=$13F0Q'#@<=0<#FL"+P3JD2PVBWEG]@F2T^V90F4- !_JSTP<#KTYHC\
M%:J;B:&:^M/L"QWT<&Q&\P"XYRW;@G'%+DI]QWD=?I6I6^L:7;:C:$F"= Z[
M@01ZCGTZ5<JCHT%W:Z-9VU\T+7,,2QN8<[#M&!C//05>K&5KZ%!1112 >OW#
M]:6D3[A^M+773^% %%%%6 4=P,C)Z9-%><:KINIW/C22Y?2KV5HKY)H;M2?*
M6".(LJ+@]6?J,=<545<3=CM--UVTU9P+1+@H1(?-:(B/Y'V$;O7(./:K%AJ5
MMJ/VG[.6(MKAK9RRX!=>H'KUKS*#0]8BM+<3Z7?2VJBSBNK:($-*I+R2 #(R
M-[*&]@:K+X8U=M/@LI-'O ]S"YM0CD1V4[S$L\ASD$(%P>?2KY%W)YF>PY&<
M9&?K1D8SD8/?->;_ /"-W5Z\<UW979DOM8DENWRP*V\8.Q?]E6*KQWS60OA_
M6);:PM+K2+^0F*W%N^XA+,&8M*&YX8#"_P"[2Y%W'S/L>O\ '/(XZ\]**\DO
M=)U>9;Z:/2]46RFU$-,QMPUU*GS':8]^'C#$ 'CCZ5UNK:9=V7P\ATVQCO;@
MH(5FC#9G:+>#(HP>N,C -)Q7<.8Z&^U:STZ:TBN7(:Z=DC(&0,*6))[# /-&
ME:I;ZQIT=];)*D$N?+,R;"X_O >A[5Y7>:9/9:3<RW6F2V=OLOGB@F)(5I66
M*)!S][;R *TE\,W4/B2SLUTBZ$%O=VODW:$B&*W1-S <]6<'=QZ4^16W%S,]
M/HH/6BLRPHHHH **** &R??_  %-IS_?_ 4VN.6[ *YK6_&$.AG5Q/:.YT^"
M&=0K<S"1MO'I@BNEKF=>\+2:QXDTV_$T:6L2%+N,CYI5&2F/H3WIPY;^]L)W
MZ#I/&VDVT]P+R7[/;1+%B<AG#,Z;\84$C P<].:-:\9:=I]AJ#6=Q#<WEG L
M[0\[0C%1DMC'1@<9S7,S?#O5W\-0Z<NI0&<32--EY%21"@2/)4@DJ%''0YJW
M/X'U29+V);FSBBGLH[?";_WKKL^9P>,C:1D<G(S6W+2ON3>1T1\9^'1I7]I'
M5(OLGF^3O"-GS ,E=N,].>G2K'_"2:.86F%_&8EACG+J"1Y;G:K=.YXK#N_"
MVJQZM/JNFW%D+K[:UQ"EPI,91H5C(..C<9%9\_@+5(K1+2QO[3RI;.."Z,L9
MR620R93'0$DCGH*GDIOJ.\CJ-"\36'B&;4(;,N'L9VAD#J1G'\0XZ'GCKQ6S
M6-HFEWFF7VKF:6%[6[NVNH-H.]2P&X-V[<8K9K*=K^[L4O,*OK]Q?I5"KZ_<
M7Z5=/J5$6BBBM2@HHHH **** "J\?_'Y/]%_K5BJ\?\ Q^3_ $7^M %BBBB@
M IK_ '?Q'\Z=37^[^(_G0 ZBBB@ J(_\?:?[A_F*EJ(_\?:?[A_F* ):***
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M -_!1SL7*B(P7I>0B]4*5P@\D?*?7KS0L%Z&B)OE(4?./)'S'UZ\5+]MM/\
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M_:K;_GXA_P"_@I?M5M_S\P_]_!1SKLOZ^8<K[O\ KY%'S]:_Z!]G_P"!1_\
MB:S+V[U>'486BMX1<N I@2X+AE]2N!CZUT/VJV_Y^8?^_@IHN+4,6$\&XC!.
M]<FJC52?PK^OF2X-]6/)<J&=0K[02H.0#CUJMIUP]WIEK<R !Y8E=@O0$C/%
M2RW5N=V+B'I_ST'I5#1;B!="T]6GB!%O&""X!'RBN"2T;\R^H]I]8#';8VA7
M/!-R1D?]\TWS]9_Y\+/_ ,"3_P#$U=^U6_\ S\0_]_!1]JM_^?B'_OX*?.OY
M5^/^8N5]W_7R*7GZS_SX6?\ X$G_ .)H\_6?^?"S_P# D_\ Q-7?M-O_ ,_$
M/_?P4?:;?_GXA_[^"CVB_E7X_P"8<K[O^OD4O/UG_GPL_P#P)/\ \31Y^L_\
M^%G_ .!)_P#B:N_:K?\ Y^(?^_@H^TV__/Q#_P!_!1[1?RK\?\PY7W?]?(I^
M?K/_ #X6G_@2?_B://UG_GPM/_ D_P#Q-7/M-O\ \_$/_?P4?:K?_GXA_P"_
M@H]HOY5^/^8<K[O^OD9\\NK/!(LEE:+&5(9OM9&!]=O%3>&KO4KB-UNHU:U3
MB*?=DM^@W#WXJRUQ;,I5IX"",$%QS5Y+RT"*/M, P/\ GH*VA57*X\J'&#YK
MW&M<N-3CML+L:)G)[Y! _K5JLI[NV_MR%OM$.T6[C.\?WA5[[;:?\_4/_?P4
MWT-$3T5!]MM/^?F'_OX*/MMI_P _,/\ W\%2,GHJ#[;:?\_4/_?P4?;;3_GZ
MA_[^"@">J\?_ !^3_1?ZTOVVT_Y^8?\ OX*C@FBDO)=DJ-N"[<,#G'6@"W11
M10 4U_N_B/YTZFO]W\1_.@!U%%% !41_X^T_W#_,5+41_P"/M/\ </\ ,4 9
M>N>(8]%NM.@: R_:Y@CL&P(4R 7/J-S*,>_M4FE^(]-UF\U&TLIB\^GS&&X4
MH1M8?7J.OY5EZ]X2DU^^O9YK^:!'LQ;VZP2%<')9BX[C=L_*KV@Z;J.G2ZA]
MMDMI%NI5G#Q9!WF-5<$$=,KD<]Z *^E^(],N[321?26L&H:C")4@]?I_3/6I
MO^$F\-_9;RZ^WVODV;A)VQ]PDX'&.<]L9SBN<MOA_/#J-A<2O!<"&"W1]T\J
M"-XLX947Y7SP?FQ@CO4</@76%74);FXM;FYN5B D>YF!WHSMYH;_ )9ME@0J
MC P1WH ZK3M?T75=7O-+LW22ZM%5I5\L@88 @@XP>HJ*SURVO?%5YHL=B-EK
M )#<Y&';=AD QVXY]3CM3M%TK4=.U*ZFN[B&Y2XAAWR@%7,J)M8XQC!QGK57
M2?"<FD>(_M\6HW$UJ+5H1#,03N:0N3G'3D^^: )Y/%?A>*:2&34[%9(Y!$ZD
MC*N6*X_,$'T[XJRVMZ$FIS::UW:B\AC,LD7&54#)_(<XZXK&D\'7#V=U$)K;
M?-;7\(;:>&GE#J?P P:CE\(ZC)-+;_:+3[#Y\UU&^&\TR21E=K=MH+$YSDC
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MW*184.TID!VYZ D<9ING^'+]-0M]2U&]@EO?M;7$X@B*1D>28E5023P#G)-
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M4 %%%% !1110!!>WMMIUI)=W<RPP1C+.W0=JY^Q\:Z9+;7-S>74,,*W<L$+
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M1_[X%'DS_P#/T?\ O@5/10!!Y,__ #]'_O@4>3/_ ,_1_P"^!4]% $'DS_\
M/T?^^!1Y,_\ S]'_ +X%3T4 0>3/_P _1_[X%'DS_P#/T?\ O@5/10!!Y,__
M #]'_O@4>3/_ ,_1_P"^!4]% $'DS_\ /T?^^!1Y,_\ S]'_ +X%3T4 0>3/
M_P _1_[X%'DS_P#/T?\ O@5/10!GM!/N/[QCSUVBD^SS_P!]_P#OD5HT5'(*
MQG?9Y_[[_P#?(H^SS_WW_P"^16C11R!8SOL\_P#??_OD4?9Y_P"^_P#WR*T:
M*.0+&=]GG_OO_P!\BC[//_??_OD5HT4<@6,[[//_ 'W_ .^11]GG_OO_ -\B
MM&BCD"Q06"?:?WC#G^Z*/(G_ .>K?]\BK]%6M%8+%#R)_P#GJW_? H\B?_GJ
MW_? J_13N+E*'D3_ //5O^^11Y$__/5O^^!5^BBX6*'D3_\ /5O^^!1Y$_\
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I?_GZ/_? I883&[NTA=FQDD8Z5-10 4444 %-?[OXC^=.I",C\: /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
